EIF3A and leukemia: In contrast to the mice injected with p185 control IMr cells, which developed leukemia within 3–4 weeks regardless whether treated with or without imatinib (Fig. 6d), all mice injected with p185 KO6.2 IMr and 4 out of 5 mice injected with p185 KO2.3 IMr showed no sign of disease for over 5 months.